TrialJournal of translational medicine2009

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma.

Antoni Ribas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.